1h Free Analyst Time
The lennox-gastaut syndrome treatment market is forecasted to grow by USD 699.8 mn during 2023-2028, accelerating at a CAGR of 4.29% during the forecast period. The report on the lennox-gastaut syndrome treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advancements in medical research on LGS, growing awareness of LGS, and increasing prevalence of LGS.
The lennox-gastaut syndrome treatment market is segmented as below:
By Type
- Non-surgical treatment
- Surgical treatment
By End-user
- Hospitals
- Specialty clinics
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the lennox-gastaut syndrome treatment market covers the following areas:
- Lennox-gastaut syndrome treatment market sizing
- Lennox-gastaut syndrome treatment market forecast
- Lennox-gastaut syndrome treatment market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global lennox-gastaut syndrome treatment market: Akron Childrens Hospital, Amneal Pharmaceuticals Inc., Aquestive Therapeutics Inc., Bausch Health Companies Inc., Cedars Sinai Health System, Cision US Inc., Eisai Co. Ltd., Epilepsy Foundation, GlaxoSmithKline Plc, H Lundbeck AS, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Marinus Pharmaceuticals Inc., Sawai Group Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, and Viatris Inc..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is rise of minimally invasive procedures for LGS.'
According to the report, one of the major drivers for this market is the advancements in medical research on LGS.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akron Childrens Hospital
- Amneal Pharmaceuticals Inc.
- Aquestive Therapeutics Inc.
- Bausch Health Companies Inc.
- Cedars Sinai Health System
- Cision US Inc.
- Eisai Co. Ltd.
- Epilepsy Foundation
- GlaxoSmithKline Plc
- H Lundbeck AS
- Jazz Pharmaceuticals Plc
- Johnson and Johnson
- Lupin Ltd.
- Marinus Pharmaceuticals Inc.
- Sawai Group Holdings Co. Ltd.
- Supernus Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- UCB SA
- Viatris Inc.